SITE Centers (SITC) News
Market Cap: $620.95M
Avg Volume: 957.14K
Industry: REIT - Retail
Sector: Real Estate
SITE Centers' First Quarter 2025 Earnings to be Released Wednesday, May 7, 2025
BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers' First Quarter 2025 Earnings to be Released Wednesday, May 7, 2025.
businesswire.com
Read More
Short Interest Down For U.S. REITs In March, Up For Advertising REITs
Average short interest in US equity real estate investment trusts decreased moderately in March. US REITs' short interest fell 3 basis points month over month to 3.7% of shares outstanding on average in March. The shopping center segment logged the biggest decline in March compared to the previous month, down 1.2 percentage points to 3.3% of shares outstanding on average.
seekingalpha.com
Read More
Should You Retain SITE Centers Stock in Your Portfolio Now?
SITC is likely to gain from its well-located portfolio, solid tenant roster and capital-recycling moves despite rising e-commerce adoption and elevated interest rates.
zacks.com
Read More
Dividend Power Dogs: 5 Ideal Safe Buys In April
Five top Dividend Power stocks with "safer" dividends include ZIM Integrated Shipping, FS KKR Capital, Mach Natural Resources, Saratoga Investment, and Golden Ocean. The Dividend Power strategy focuses on high earnings and dividend yields, creating a portfolio resilient in downturns and profitable in bull markets. Analysts project significant gains (49.51% to 140.25%) for the top ten Dividend Power stocks by April 2026, with an average net gain of 92.52%.
seekingalpha.com
Read More
SITE Centers: Cost Control Key After Curbline Properties Spin-Off
SITE Centers is a retail REIT focused on open-air shopping centers in high-income communities. The REIT's Q4 2024 results show it is slow to adapt general and administrative expenses to a much smaller asset base. I compare SITC's administrative overhead to Simon Property Group, showing room for substantial improvement.
seekingalpha.com
Read More
CERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting
SOUTH SAN FRANSCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces it is presenting encouraging preclinical results of lead compound CER-1236 in ovarian cancer during the 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors in San Diego, March 12-14.
globenewswire.com
Read More
Dividend Power Dogs: 3 Top Dividend Picks For March
Three top Dividend Power stocks, Golden Ocean, Diversified Energy, and Saratoga Investment Corp, offer "safer" dividends with free cash-flow yields exceeding dividend yields. The Dividend Power strategy focuses on high earnings yield and top dividend yield stocks, creating a resilient portfolio for both downturns and bull markets. Analysts predict significant net gains (39.97% to 168.6%) for the top ten Dividend Power stocks by March 2026, with an average net gain of 77.96%.
seekingalpha.com
Read More
Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the acceptance of two abstracts for poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting taking place March 12-14, 2025, in San Diego, C.A. Details of the poster presentation are as follows: Abstract Ti.
businesswire.com
Read More
SITE Centers Stock Declines on Q4 OFFO & Revenue Estimate Miss
SITC's fourth-quarter results reflect a year-over-year fall in revenues and leased rate.
zacks.com
Read More
Here's What Key Metrics Tell Us About SITE Centers Corp. (SITC) Q4 Earnings
The headline numbers for SITE Centers Corp. (SITC) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
zacks.com
Read More
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting
FRAMINGHAM, MA / ACCESS Newswire / February 27, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting being held March 12 - 14, 2025 in San Diego, CA and virtually. Details for the presentation are as follows: Abstract Number: 123 Title: DNase I Intervention Enhances CAR-T Cell Therapy in Solid Tumors by Targeting Neutrophil Extracellular Traps in Metastatic Melanoma Presenter: Alexey Stepanov, PhD, Institute Investigator at The Scripps Research Institute Date & Time: Wednesday, March 12, 2025 at 5:10 p.m.
accessnewswire.com
Read More
SITE CENTERS CORP. (SITC) Misses Q4 FFO and Revenue Estimates
SITE CENTERS CORP. (SITC) came out with quarterly funds from operations (FFO) of $0.16 per share, missing the Zacks Consensus Estimate of $0.23 per share.
zacks.com
Read More
SITE Centers Reports Fourth Quarter 2024 Results
BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Reports Fourth Quarter 2024 Results.
businesswire.com
Read More
SITE Centers' Fourth Quarter 2024 Earnings to Be Released Thursday, February 27, 2025
BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers' Fourth Quarter 2024 Earnings to be Released Thursday, February 27, 2025.
businesswire.com
Read More
SITE Centers Announces Tax Allocations of 2024 Dividend Distributions
BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Announces Tax Allocations of 2024 Dividend Distributions.
businesswire.com
Read More
69 Graham Value All-Stars, Of 20 'Safer' Choices, Buy Any Of 14
The Value Score identifies large-cap stocks offering the best value relative to their assets and profits, focusing on low-priced, high-value investments. The Ben Graham Formula targets ultra-stable stocks with strong earnings, dividends, and low valuations, ensuring long-term stability and minimal losses. Analysts forecast significant gains (29.57% to 79.74%) for top-ten GASV stocks by January 2026, highlighting high-yield, low-risk investment opportunities.
seekingalpha.com
Read More
4 Of 35 Safe-Buy Dividend Power Dogs In January
Four low-priced Dividend Power stocks, Golden Ocean, Invesco Mortgage, ARMOUR Residential, and FutureFuel, offer safer dividends with free cash-flow yields exceeding dividend yields. The Dividend Power strategy focuses on high earnings yield and top dividend yield stocks, creating a resilient portfolio for both downturns and bull markets. Analysts project significant gains for top Dividend Power stocks, with an average net gain of 79.97% on $10k invested in the top ten.
seekingalpha.com
Read More
Of 36 Dividend Power Dogs, 11 Are Buyable In November
Eleven of the 35 Dividend Power Dogs are recommended for their "safer" dividends, with free cash-flow yields exceeding dividend yields, making them ideal buys. The Dividend Power strategy focuses on high earnings yield and high dividend yield, creating a resilient portfolio for both downturns and bull markets. Analysts project significant gains for the top ten DiviPower stocks by November 2025, with potential net gains ranging from 55.4% to 108.51%.
seekingalpha.com
Read More
SITE Centers Announces Tax Estimate for Curbline Properties Distribution
BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Announces Tax Estimate for Curbline Properties Distribution.
businesswire.com
Read More
CBL & Associates Properties Vs. SITE Centers: Which Is The Better REIT For 2025
CBL & Associates Properties and SITE Centers are REITs focused on retail real estate, with reported occupancy rates indicating poor competitive dynamics. CBL funds a greater proportion of its capital structure with debt, but both companies have significant floating rate debt exposure. CBL is more attractively valued on an enterprise-level and AFFO multiple basis, but also reports higher administrative expenses.
seekingalpha.com
Read More
HOOKIPA Pharma's Eseba-vec Highlighted in SITC Late-Breaker
Phase 2 trial evaluating eseba-vec/pembrolizumab combination resulted in a 52% ORR in PD-L1 CPS>20 patients and encouraging PFS and OS data, supported by highly durable and tumor-specific T cell response, with good overall safety Phase 2 trial evaluating eseba-vec/pembrolizumab combination resulted in a 52% ORR in PD-L1 CPS>20 patients and encouraging PFS and OS data, supported by highly durable and tumor-specific T cell response, with good overall safety
globenewswire.com
Read More
Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME
Two oral presentations and multiple posters on clinical and preclinical-stage candidates to be presented at SITC, demonstrating the strength of Immatics' TCR-T PRAME franchise to target solid cancers
globenewswire.com
Read More
Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Data continues positive trend as additional patients are enrolled in 3 cohorts Vaccine was safe and well tolerated by participants in all 3 cohorts Protocol defined immune responses were exhibited in over 70% of patients A Phase 2 study evaluating the vaccine in the neoadjuvant setting is planned to commence in 2025 SAN JOSE, Calif. , Nov. 8, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced a presentation of new, updated positive data from the Phase 1 clinical trial of its breast cancer vaccine (NCT04674306) at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, being held in Houston, Texas.
prnewswire.com
Read More
Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
BOSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced its poster presentation entitled “Pharmacodynamic and Response Biomarkers in the Monotherapy Arm of a Phase 1 Trial of CTX-471, a Novel Anti-CD137 Agonist Antibody” at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting, from November 6-10, 2024 in Houston, TX.
globenewswire.com
Read More
Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” BiSKIT (Bifunctional SuperKine for ImmunoTherapy), engineered to deliver an anti-PD1-IL-2 Superkine (anti-PD1-IL-2 SK ) to the tumor microenvironment (TME), where it is conditionally activated by tumor-associated proteases
globenewswire.com
Read More
BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference
PHILADELPHIA and VANCOUVER, British Columbia, Nov. 08, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today is pleased to report preclinical data showing strong anti-cancer activity of its next generation, personalized, off-the-shelf, cell-based breast and prostate cancer immunotherapies, Bria-BRES+™ and Bria-PROS+™, respectively, during a poster session at the 2024 Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, held November 6-10, 2024, in Houston, TX.
globenewswire.com
Read More
Innate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that new preclinical data supporting the clinical development of its proprietary next generation antibody-drug conjugate (ADC) and innovative tetra-specific ANKET® will be presented at the SITC Annual Meeting 2024. “We are thrilled to share our latest preclinical data at the SITC Annual Meeting, highlighting the potential of IPH6501, our tetra-spe.
businesswire.com
Read More
Akeso Published Mechanism of Action for CLDN18.2/CD47 Bispecific Antibody AK132 for the First Time at SITC Annual Meeting
HONG KONG , Nov. 7, 2024 /PRNewswire/ -- At the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024), held in Houston, USA, from November 6 - 10, Akeso Biopharma (9926. HK) presented the mechanism of action (MOA) research findings of its innovative bispecific antibody, AK132, targeting both Claudin18.2 (CLDN18.2) and CD47.
prnewswire.com
Read More
Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Less frequent IV dosing with nemvaleukin in patients with select advanced solid tumors, including ovarian cancer and mucosal melanoma, showed tumor site-specific pharmacodynamic activity and immune activation
globenewswire.com
Read More
Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual Meeting
Preliminary data demonstrate durable and dose-dependent T cell responses targeting KRAS mutations and induced responses to patient-specific neoantigens
globenewswire.com
Read More
Strong Evidence of AU-007's Anti-Tumor Activity in Advanced Solid Tumor Cancers Presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting
LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of potentially best-in-class IL-2 therapeutics, today shared positive results from its Phase 1/2 dose escalation and cohort expansion study of AU-007. The data will be presented in a poster session at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting in Houston, Texas. Preliminary Phase 2 data reveal that a combination of AU-007 and low-dose,.
businesswire.com
Read More
Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting
– NKTR-255 administered post completion of concurrent chemoradiation and in combination with durvalumab demonstrated statistically significant lymphocyte recovery compared to historical controls at week 8 – – Pharmacodynamic data show NKTR-255 increased NK cell proliferation and markers of NK cell activation – SAN FRANCISCO , Nov. 7, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) and collaborators at The University of Texas MD Anderson Cancer Center today presented late-breaking results from a Phase 2 study evaluating NKTR-255 for the treatment of radiation induced lymphopenia after concurrent chemoradiation in locally advanced non-small cell lung cancer (NSCLC) patients at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting. NKTR-255 is a novel polymer-conjugated IL-15 agonist, designed to activate, proliferate and expand natural killer (NK) and CD8+ T-cells, as well as to promote the survival and expansion of memory CD8+ T cells.
prnewswire.com
Read More
AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024.
businesswire.com
Read More
Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
- Improved safety and efficacy profiles for ADG126 versus ipilimumab driven by precision masking, novel epitope-dependent antibody-dependent cellular cytotoxicity (ADCC) and partial CTLA-4 blockade -
globenewswire.com
Read More
Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Presenting new clinical data from Phio's on-going Phase 1b trial Marlborough, Massachusetts--(Newsfile Corp. - November 7, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company creating new pathways towards a cancer-free future by using its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio announced today that it is presenting clinical data from its on-going Phase 1b clinical trial at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which will be held in Houston, TX from November 8-10, 2024.
newsfilecorp.com
Read More
MiNK's iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024
AgenT-797 Combination with Checkpoint Inhibitors and Bispecific Engagers Expands Anti-Cancer Benefit PRAME-TCR iNKT Overcomes Challenges from Conventional TCR-T Cells in Solid Cancers NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced data from two poster presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting in Houston, Texas. The presentations showcased new data from MiNK's iNKT cell therapy programs, agenT-797 and PRAME-TCR.
globenewswire.com
Read More
Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting
- Interim phase 1 clinical trial update reveals the clinical potential of the tumor-activated IL-12 prodrug WTX-330, with favorable tolerability profile and encouraging efficacy signals -
globenewswire.com
Read More
Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting
NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, announces compelling safety, pharmacokinetics, and biomarker data on its lead compound, Decoy20, at the Society for Immunotherapy of Cancer (SITC) 2024 annual meeting. The data derive from two cohorts (13 patients) of Decoy20 single administration and one cohort (6 patients) of Decoy20 weekly administration in the Company's ongoing Phase 1 clinical trial.
globenewswire.com
Read More
ONCOTELIC CLINICAL PRESENTATIONS AT SITC 2024
AGOURA HILLS, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its presentation at SITC 2024. Dr. Cynthia Lee, VP of R&D will be presenting Sapu Bio pipeline of TGFB2 therapeutics. For additional information please go to: https://www.sitcancer.org/home .
globenewswire.com
Read More
Anixa Biosciences Announces Timing of Public Release of Data from the Phase 1 Study of its Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
SAN JOSE, Calif. , Nov. 6, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the presentation of additional data from the Phase 1 clinical trial of its breast cancer vaccine at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, will be made publicly available on the Company's website at 12:15pm CT on November 8, 2024.
prnewswire.com
Read More
BIO-TECHNE TO PRESENT AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 39TH ANNUAL MEETING
MINNEAPOLIS , Nov. 6, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its market-leading portfolio to advance cancer research from target discovery to personalized medicine and cell therapy development at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, taking place November 6-10, 2024, in Houston, Texas. Bio-Techne's spatial biology brands, Advanced Cell Diagnostics (ACD) and Lunaphore, are revolutionizing spatial biology research with their pioneering innovations that are advancing the development of tailored immunotherapies to improve patient outcomes.
prnewswire.com
Read More
MAIA Biotechnology Announces Late-Breaking Abstract of THIO-101 Updates Selected for Oral and Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Late-Breaking Abstract of THIO-101 Updates Selected for Oral and Poster Presentation at the SITC 39th Annual Meeting.
businesswire.com
Read More
Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma
NEEDHAM, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced preclinical results and therapeutic potential of CAN-3110 in the Ras-Raf pathway altered melanoma model. The data will be presented at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, taking place November 6-10, in Houston, Texas by Anne R. Diers, PhD, Senior Director of Research at Candel Therapeutics.
globenewswire.com
Read More
SITE Centers Q3 OFFO & Revenues Miss Estimates, Stock Falls
SITC's third-quarter results reflect a year-over-year fall in revenues and base rent per square foot.
zacks.com
Read More
Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit
Poster presentation at SITC to highlight extended follow-up data from AMPLIFY-7P Phase 1 study Oral presentation at SU2C Innovation Summit to highlight data from AMPLIFY-7P and AMPLIFY-201 Phase 1 studies BOSTON, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced two upcoming presentations in November. The first presentation will take place at the upcoming Society for Immunotherapy of Cancer (“SITC”) 39th Annual Meeting, being held November 6-10, 2024, in Houston, Texas.
globenewswire.com
Read More
Scholar Rock to Present New Clinical and Biomarker Data from the Phase 1 DRAGON Trial at the SITC 39th Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, announced today that it will present data from the Phase 1 DRAGON trial of SRK-181, an investigational selective inhibitor of latent TGFβ1 activation, in patients with advanced solid tumors at the Society for I.
businesswire.com
Read More
Compared to Estimates, SITE Centers Corp. (SITC) Q3 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for SITE Centers Corp. (SITC) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
zacks.com
Read More
SITE CENTERS CORP. (SITC) Q3 FFO and Revenues Miss Estimates
SITE CENTERS CORP. (SITC) came out with quarterly funds from operations (FFO) of $0.81 per share, missing the Zacks Consensus Estimate of $0.87 per share.
zacks.com
Read More
Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Late-breaking abstract featuring IGNYTE clinical trial data, including subgroup and initial biomarker analyses, selected for oral presentation
globenewswire.com
Read More
Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
WALTHAM, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that initial data from its Phase 1C dose escalation of XTX101 (vilastobart) in combination with atezolizumab in patients with advanced solid tumors will be presented in a late-breaker poster session at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting taking place in Houston, Texas, from November 6-10, 2024.
globenewswire.com
Read More
SITE Centers Reports Third Quarter 2024 Results
BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Corp. (NYSE: SITC), an owner of open-air shopping centers primarily in suburban, high household income communities, announced today operating results for the quarter ended September 30, 2024. "SITE Centers completed the planned spin-off of Curbline Properties on October 1, unlocking a unique and scalable opportunity focused on convenience real estate and providing investors with two distinct business plans,” commented David R. Lukes, President and.
businesswire.com
Read More
I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024
- Poster to be presented in a late-breaking abstract session at the Society for Immunotherapy of Cancer (SITC) on Saturday, November 9, 2024 ROCKVILLE, Md. , Oct. 30, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced the presentation of a poster highlighting Phase 1 optimized dose estimation data for givastomig monotherapy (TJ033721/ABL111), a novel first-in-class Claudin18.2 (CLDN18.2) and 4-1BB bispecific antibody, at SITC 2024.
prnewswire.com
Read More
Anixa Biosciences and Cleveland Clinic to Present Additional Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
SAN JOSE, Calif. , Oct. 28, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced a presentation of additional data from the Phase 1 clinical trial of its breast cancer vaccine at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, being held virtually and in Houston, Texas, from November 6-10, 2024.
prnewswire.com
Read More
CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / October 28, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced poster presentations at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, taking place November 8-10 in Houston, USA.
accesswire.com
Read More
67 October Graham All-Star Value Dogs Show 55 Fit To Buy
The Value Score identifies large-cap stocks offering high-value relative to profits, cash flows, assets and sales, aiding in finding undervalued companies.
seekingalpha.com
Read More
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024
FRAMINGHAM, MA / ACCESSWIRE / October 22, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat oncology indications, today announced its abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting being held November 6-10, 2024, in Houston, Texas and virtually. Details of the presentation are as follows: Title: DNase I Targeting of Neutrophil Extracellular Traps Improves CTLA-4 Immune Checkpoint blockade in Models of MSS/MMRp CRC Abstract Number: 765 Presenter: Reid Bissonnette, Ph.D.
accesswire.com
Read More
SITE Centers' Third Quarter 2024 Earnings to be Released Wednesday, October 30, 2024
BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Corp. (NYSE: SITC) announced today that it intends to release its third quarter earnings prior to the market open on October 30, 2024. About SITE Centers Corp. SITE Centers is an owner and manager of open-air shopping centers located primarily in suburban, high household income communities. The Company is a self-administered and self-managed REIT operating as a fully integrated real estate company, and is publicly traded on the New York Stock Excha.
businesswire.com
Read More
Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting
PHILADELPHIA, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced a poster regarding the Company's clinical asset, CTIM-76, a Claudin 6 x CD3 bispecific antibody will be presented at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting, being held November 8–10, 2024 at the George R. Brown Convention Center in Houston, TX.
globenewswire.com
Read More
Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
SAN DIEGO and SUZHOU, China, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced poster presentations at the upcoming SITC 39th Annual Meeting, taking place in Houston, Nov. 6 – 10, 2024.
globenewswire.com
Read More
Mural Oncology to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
WALTHAM, Mass and DUBLIN, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced three upcoming poster presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) taking place November 6-10, 2024 in Houston.
globenewswire.com
Read More
Beyond Cancer to Present Preclinical Data of Ultra-High Concentration Nitric Oxide (UNO) Low Volume Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
HAMILTON, Bermuda, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, today announced being selected to present two poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024, which is scheduled to be held November 6–10 at the George R. Brown Convention Center in Houston, Texas. Abstracts are scheduled to be released to SITC registrants on November 5, 2024, 9:00 AM U.S. ET.
globenewswire.com
Read More
MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024
NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced two poster presentations at the Society for Immunotherapy of Cancer's (SITC) 29th Annual Meeting on November 6-10, 2024, in Houston, Texas. The presentations will showcase new preclinical data from MiNK's iNKT cell programs, agenT-797 and PRAME-TCR.
globenewswire.com
Read More
Medicenna to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Updated clinical results to be presented from the ongoing Phase 1/2 ABILITY-1 study of MDNA11 in advanced or metastatic solid tumors
globenewswire.com
Read More
Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
WALTHAM, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced an upcoming poster presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting taking place in Houston, Texas, from November 6-10, 2024. The company plans to present preclinical data from its tumor-activated SELECTIVE EFFECTOR-ENHANCED CELL ENGAGER (SEECR) format.
globenewswire.com
Read More
Carisma Therapeutics Announces Upcoming Presentations at SITC 2024
PHILADELPHIA , Oct. 4, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced its upcoming poster presentations at the Society for Immunotherapy of Cancer (SITC), taking place in Houston, Texas, November 6 -10, 2024. Details on the poster presentations at SITC 2024 are below: Title: Pre-clinical efficacy of a novel anti-GPC3 in vivo CAR-M for hepatocellular carcinoma Publication Number: 329 Session Date & Time: Friday, Nov. 8, 2024 Location: Exhibit Halls A B George R.
prnewswire.com
Read More
Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024
SEATTLE, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (OTC Pink: KANT) , a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that its abstract on the KVA12123 clinical program has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting to be held November 6-10, 2024, in Houston, Texas and virtually.
globenewswire.com
Read More
Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting
NEEDHAM, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the Company will present a poster at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting taking place November 6-10, 2024 in Houston, Texas and virtually.
globenewswire.com
Read More
IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting
NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced two abstracts accepted for poster presentation at the Society for Immunotherapy of Cancer's 39th Annual Meeting (SITC 2024) taking place taking place in Houston, Texas on November 8-10, 2024.
globenewswire.com
Read More
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting
BOSTON, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced it will deliver an oral and a poster presentation on the company's Immuno-STAT™ clinical assets CUE-101 and CUE-102, representative of the CUE-100 series, at the Society for Immunotherapy of Cancer's 39th Annual Meeting (SITC 2024). The conference will be held in Houston, Texas, on November 6-10, 2024.
globenewswire.com
Read More
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting
WATERTOWN, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced that two posters will be presented at the upcoming Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting, taking place November 6-10, 2024, in Houston, Texas.
globenewswire.com
Read More
Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
SOUTH SAN FRANCISCO, Calif., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors or hematologic malignancies, announced today that three abstracts highlighting its pipeline of clinical product candidates and anti-exhaustion technology have been accepted for presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) taking place in Houston, TX, Nov. 6-10, 2024.
globenewswire.com
Read More
AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024.
businesswire.com
Read More
Curbline Properties Announces Tax Basis
NEW YORK--(BUSINESS WIRE)--On October 1, 2024, Curbline Properties Corp. (NYSE: CURB) (“CURB” or “Curbline”) completed its separation from SITE Centers Corp. (NYSE: SITC) (“SITC”) and became an independent publicly traded company. In the separation, SITC distributed two CURB common shares for every SITC common share held by SITC shareholders on the close of business on September 23, 2024 (the “Distribution”). The fair market value of CURB's common stock received by SITC shareholders in the Dist.
businesswire.com
Read More
SITC Closes Curbline Spin-Off, Disposes Properties Worth $610.1M
SITE Centers announces completion of Curbline spinoff. It also provides an update on its transaction activity from Sept.
zacks.com
Read More
SITE Centers: Curbline Properties IPO Prices In Line With Valuations
SITE Centers Corp. is a retail REIT focused on retail locations close to residents with a high household income. The company successfully spun off its premium assets in a new REIT called Curbline Properties, achieving a 6% cap rate. Curbline Properties focuses on high-income convenience retail with strong leasing spreads and limited capital expenditure needs.
seekingalpha.com
Read More
SITE Centers Announces Completion of Spin-Off of Curbline Properties
BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Corp. (NYSE: SITC) (the “Company” or “SITE Centers”) today announced that it has completed the previously announced spin-off of Curbline Properties Corp. (“Curbline”), which is now an independent, publicly traded company that will begin regular-way trading today on the New York Stock Exchange (“NYSE”) under the ticker symbol “CURB.” Curbline is an owner of convenience shopping centers positioned on the curbline of well-trafficked intersections and.
businesswire.com
Read More
SITE Centers Provides Transaction and Curbline Balance Sheet Update
BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Corp. (NYSE: SITC) (the “Company” or “SITE Centers”), an owner of open-air shopping centers in suburban, high household income communities, today provided an update on transaction activity along with updated projected Curbline Properties Corp. (“Curbline”) balance sheet information. From September 17, 2024 to September 27, 2024, SITE Centers sold 11 wholly owned properties for an aggregate gross price of $610.1 million. As a result of disposition a.
businesswire.com
Read More
SITE Centers Disposes Shopping Centers for $714M, Acquires for $111M
SITC provides an update on its transaction and financing activities in Q3 2024 through Sept. 17, 2024, which displays its prudent capital-management practices.
zacks.com
Read More
Shopping Center REITs Are Hot: Pick A Winner
The current environment is favorable for REITs, with normalized prices, falling Treasury yields, and expected prime rate cuts. Shopping Center REITs offer above-average yields (3.88%) and superior growth prospects, driven by record-high occupancy rates and strong rental rate spreads. This article examines liquidity, FFO growth, TCFO growth, dividend growth, market cap, share price growth, and volatility to identify the best Shopping Center REITs for the next 2 years.
seekingalpha.com
Read More
BriaCell Announces Presentation at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 09, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces a poster presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, held November 6-10, 2024, in Houston, TX.
globenewswire.com
Read More
Curbline Properties Publicly Files Form 10 with SEC
BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Corp. (NYSE: SITC) (the “Company” or “SITE Centers”) today announced that, in connection with the Company's previously announced plan to spin-off its portfolio of convenience assets into a separate publicly traded company, on September 3, 2024, Curbline Properties Corp. (“Curbline”) publicly filed a Registration Statement on Form 10 (the “Form 10”) with the Securities and Exchange Commission (the “SEC”), which is available at www.sec.gov. The compl.
businesswire.com
Read More
SITE Centers Disposes of 11 Shopping Centers and Acquires 4
SITC provides an update on its transaction and financing activities in Q3 2024 through Aug. 29, 2024, which displays its prudent capital-management practices.
zacks.com
Read More
SITE Centers Provides Third Quarter 2024 Transaction and Financing Update
BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Corp. (NYSE: SITC), an owner of open-air shopping centers in suburban, high household income communities, today provided an update on third quarter 2024 to date transaction and financing activity. In the third quarter to date, SITE Centers has sold 11 wholly owned properties for an aggregate gross price of $552.7 million and acquired four convenience shopping centers for an aggregate gross price of $88.0 million including Crocker Commons (Cleveland.
businesswire.com
Read More
69 All Star And Graham Value Stocks; 49 Fit To Buy In August
Large Cap Value ranking by YCharts focuses on intrinsic firm value of large cap stocks. The Ben Graham Formula strategy selects stable stocks based on earnings, dividends, and valuation based on Graham's book “The Intelligent Investor”. 49 out of 69 All-Star Value Dividend stocks offer annual dividends (from $1K invested) exceeding their price per share. 5 of the 69 showed yields exceeding 25% and were disqualified as unsustainable.
seekingalpha.com
Read More
SITE Centers (SITC) Q2 OFFO Beat Estimates, Stock Rises
SITE Centers' (SITC) second-quarter results benefit from growth in base rent per square foot and same-store NOI.
zacks.com
Read More
SITE Centers Corp. (SITC) Q2 2024 Earnings Call Transcript
SITE Centers Corp. (NYSE:SITC ) Q2 2024 Earnings Conference Call July 30, 2024 8:00 AM ET Company Participants Stephanie Ruys de Perez – Vice President-Capital Markets David Lukes – Chief Executive Officer Conor Fennerty – Chief Financial Officer Conference Call Participants Dori Kesten – Wells Fargo Craig Mailman – Citi Todd Thomas – KeyBanc Capital Markets Samir Khanal – Evercore ISI Floris van Dijkum – Compass Point Ronald Kamdem – Morgan Stanley Linda Tsai – Jefferies Alexander Goldfarb – Piper Sandler Paulina Rojas – Green Street Ki Bin Kim – Truist Jianfeng Wang – JPMorgan Operator Good day and welcome to the SITE Centers' Second Quarter 2024 Operating Results Conference Call. All participants will be in listen-only mode.
seekingalpha.com
Read More
SITE Centers Corp. (SITC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for SITE Centers Corp. (SITC) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
zacks.com
Read More
SITE CENTERS CORP. (SITC) Q2 FFO Beat Estimates
SITE CENTERS CORP. (SITC) came out with quarterly funds from operations (FFO) of $0.27 per share, beating the Zacks Consensus Estimate of $0.24 per share.
zacks.com
Read More
SITE Centers' Second Quarter 2024 Earnings Conference Call to be Held on Tuesday, July 30, 2024, at 8:00 a.m. Eastern Time
BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Corp. (NYSE: SITC), an owner of open-air shopping centers in suburban, high household income communities, announced today that financial and operational results for the quarter ended June 30, 2024 will be released prior to the market open on July 30, 2024. The Company will host its quarterly earnings conference call and audio webcast on July 30, 2024, at 8:00 a.m. Eastern Time. All interested parties can access the earnings call by dialing 888-317-.
businesswire.com
Read More
Should You Retain SITE Centers (SITC) Stock in Your Portfolio?
SITE Centers (SITC) is likely to gain from its well-located portfolio, solid tenant roster and capital-recycling moves, despite rising e-commerce adoption and high interest rates.
zacks.com
Read More
SITE Centers Announces Sale of Six-Property Portfolio
BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Corp. (NYSE: SITC), an owner of open-air shopping centers in suburban, high household income communities, announced today that it has closed on the sale of a six-property portfolio to an affiliate of Pine Tree for a price of $495 million prior to closing pro-rations, allocations and credits. The sale excluded 93,607 square feet of gross leasable area at three properties retained by the Company and intended to be included in the expected spin-off of.
businesswire.com
Read More
SITE Centers (SITC) Disposes Two Properties for $50M in Q2
SITE Centers (SITC) provides an update on its transaction and financing activities for second-quarter 2024, which displays its prudent capital-management practices.
zacks.com
Read More
SITE Centers Provides 2024 Transaction and Financing Update
BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Corp. (NYSE: SITC), an owner of open-air shopping centers in suburban, high household income communities, today provided an update on second quarter 2024 transaction and financing activity in connection with presentations at NAREIT's REITweek Investor Conference. “SITE Centers has closed on the sale of two properties in the second quarter to date for an aggregate gross sale price of $50.2 million bringing total dispositions since June 30, 2023 to $.
businesswire.com
Read More
SITE Centers Declares Second Quarter 2024 Class A Preferred Share Dividend
BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Corp. (NYSE: SITC), an owner of open-air shopping centers in suburban, high household income communities, today declared its second quarter 2024 Preferred Class A stock dividend of $0.39844 per depositary share. Each Class A depositary share is equal to one-twentieth of a share of SITE Centers' 6.375% Class A Cumulative Redeemable Preferred Stock. The declared Preferred Class A dividend covers the period beginning April 15, 2024 and ending July 14,.
businesswire.com
Read More
SITE Centers Corp. (SITC) Up 1.9% Since Last Earnings Report: Can It Continue?
SITE Centers Corp. (SITC) reported earnings 30 days ago. What's next for the stock?
zacks.com
Read More
Should You Retain SITE Centers (SITC) in Your Portfolio Now?
A well-located portfolio, solid tenant roster and capital-recycling moves bode well for SITE Centers (SITC). However, rising e-commerce adoption and high interest rates are key woes.
zacks.com
Read More
SITE Centers (SITC) Stock Declines Despite Q1 OFFO Beat
SITE Centers' (SITC) first-quarter results benefit from growth in base rent per square foot and same-store NOI.
zacks.com
Read More
SITE Centers Corp. (SITC) Q1 2024 Earnings Call Transcript
SITE Centers Corp. (NYSE:SITC ) Q1 2024 Earnings Conference Call April 30, 2024 8:00 AM ET Company Participants Stephanie Ruys - Vice President, Capital Markets David Lukes - Chief Executive Officer Conor Fennerty - Chief Financial Officer Conference Call Participants Dori Kesten - Wells Fargo Craig Mailman - Citi Alexander Goldfarb - Piper Sandler Todd Thomas - KeyBanc Capital Ronald Kamdem - Morgan Stanley Floris Van Dijkum - Compass Point Samir Khanal - Evercore ISI Michael Mueller - JPMorgan Paulina Rojas - Green Street Linda Tsai - Jefferies Ki Bin Kim - Truist Michael Gorman - BTIG Operator Good day and welcome to the SITE Centers' First Quarter 2024 Operating Results Conference Call. All participants will be in a listen-only mode.
seekingalpha.com
Read More
SITE Centers Corp. (SITC) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for SITE Centers Corp. (SITC) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
zacks.com
Read More
SITE CENTERS CORP. (SITC) Q1 FFO and Revenues Top Estimates
SITE CENTERS CORP. (SITC) came out with quarterly funds from operations (FFO) of $0.28 per share, beating the Zacks Consensus Estimate of $0.24 per share.
zacks.com
Read More